WHC is still in active development. Read this to understand our approach.
depiction of AEMFNILZOJDQLW-UHFFFAOYSA-N.svg
isomerdesign

Androstenedione

Check on isomerdesign

pubchem

Androstenedione

Check on pubchem

drugmap

4-ANDROSTENE-3-17-DI...

Check on drugmap

Data

InChI: InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-16H,3-10H2,1-2H3

Synonyms: UNII-409J2J96VR,Δ4-dione,Androstendione,BDBM91713,Androtex,NSC-9563, ANDROSTENEDIONE, delta-4-Androstenedione,NCGC00259818-01,STK801871,ANDROSTENEDIONE [VANDF],NCGC00254238-01,(3aS,3bR,9aR,9bS,11aS)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione,Tox21_110893,CAS-63-05-8,DSSTox_CID_4523,MLS002152886,409J2J96VR,Androstenedione (JAN),Testosterone EP Impurity A,Androstenedione (Androst-4-ene-3,17-dione) 1.0 mg/ml in Acetonitrile, Androst-4-ene-3,17-dione,D4-Androstene-3,17-dione,AKOS005622710,DELTA4-Androstene-3,17-dione,[4-14C]androst-4-ene-3,17-dione,Tox21_110893_1,SCHEMBL23272, 4-Androstene-3,17-dione,Tox21_202269,Androstenedione; 3,17-Dioxo-4-andostene,adione,(4)-Androsten-3,17-dione,SR-01000003096-4,delta4-androstenedione,delta-(sup4)-Androsten-3,17-dione, NSC 9563,NCGC00023902-07,delta-4-Androstene-3,17-dione,SR-01000075697-1,ANDROSTENEDIONE [MART.],CHEBI:16422, SKF 2170,LMST02020007,ANDROSTENEDIONE [MI],BIDD:PXR0101,AC-11042, delta-4-Androstene-3,17-dione,(8R,9S,10R,13S,14S)-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione,c1015,(8R,10R,13S)-10,13-Dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-2H-cyclopenta[a]phenanthrene-3,17-dione,NCGC00023902-03, Androtex,androstenedione, Androstendione,Spectrum5_002059,8F5F4DCB-1164-4F2C-B4E3-3B74F684B189,androst-4-ene-3,17-dione (androstenedione),delta-4-Androstenedione,.DELTA.4-Androstene-3,17-dione,ANDROSTENEDIONE [HSDB],Q411064, EINECS 200-554-5,3,17-Dioxoandrost-4-ene,4-Androstene-3,17-dione, delta-(sup4)-Androsten-3,17-dione,4-Androsten-3,17-dione, 1963/5/8,NCGC00023902-05, Androstenedione [JAN],Delta(4)-androsten-3,17-dione,A0845,NCGC00023902-08,DB01536,HSDB 7335,SKF 2170,Androstenedione (Androst-4-ene-3,17-dione), 4-Androstenedione, d4-androstenedione,.delta.4-Androsten-3,17-dione,D00051,Tox21_300579,DSSTox_GSID_24523,DTXSID8024523,NCGC00023902-06,SR-01000075697,DSSTox_RID_77443,HMS2231F18,NSC9563,MLS000028510,NCGC00023902-04, MLS000028510,GTPL2860,TESTOSTERONE IMPURITY A [EP IMPURITY], androstenedione,CHEMBL274826,Androstenedione, delta(sup 4)-Androstene-3,17-dione,ZINC4428526,C00280,EU-0100114,Opera_ID_1694,W-104936,delta(sup 4)-Androstene-3,17-dione,63-05-8,delta-4-Androsten-3,17-dione,4-Androstenedione,4-ANDROSTENE-3-17-DIONE,4-ANDENDION,17-Ketotestosterone,VS-12118,A4, Fecundin, NSC9563,AC-33197,Androst-4-ene-3,17-dione,androst-4-en-3,17-dione,SMR000058281,.delta.-(sup4)-Androsten-3,17-dione,4-Androstene-3,17-dione, VETRANAL(TM), analytical standard,CCG-204209,Androstenedione [JAN],NSC 9563, UNII-409J2J96VR,A 9630,Delta(4)-androstene-3,17-dione,Androst-4-ene-3,17-dione; 17-Ketotestosterone; Androstenedione; 4-Androstene-3,17-dione; 4-Androstenedione,Epitope ID:135869,MLS000563086,EC 200-554-5, 3,17-Dioxoandrost-4-ene,SR-01000003096,NCGC00023902-09,BBL033517,EINECS 200-554-5,TESTOSTERONE RELATED COMPOUND A [USP-RS],ANDROSTENEDIONE [WHO-DD],Lopac0_000114,Androst-4-en-3,17-dione, 2, CHEBI:16422,(8R,9S,10R,13S,14S)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione,Fecundin,Estr-5-ene-3,17-diol,(3b,17b)-, 17-Ketotestosterone,[4-14C]-androstenedione, delta-4-Androsten-3,17-dione, 4-Androsten-3,17-dione, HSDB 7335,FT-0657562,WLN: L E5 B666 FV OV MUTJ A1 E1,117598-81-9,Androsten-3,17-dione


Estimated data

Solubility: -4.408 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 69.4% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.